Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: A nested case-control study

Diabetes, Obesity and Metabolism

Volumn 16, Issue 1, 2014, Pages 22-29

  Abdelmoneim, A S ^a   Eurich, D T ^a   Gamble, J M ^b   Johnson, J A ^a   Seubert, J M ^a   Qiu, W ^a   Simpson, S H ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Acute coronary syndrome; Ischaemic conditioning; Nested case control study; Sulfonylurea

Indexed keywords

ACARBOSE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; DIGOXIN; GLIBENCLAMIDE; GLICLAZIDE; GLITAZONE DERIVATIVE; INSULIN; METFORMIN;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; CANADA; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; CORONARY RISK; DIABETIC PATIENT; FEMALE; FOLLOW UP; HEART DEATH; HOSPITALIZATION; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PNEUMONIA; RISK ASSESSMENT;

ACUTE CORONARY SYNDROME; ISCHAEMIC CONDITIONING; NESTED CASE-CONTROL STUDY; SULFONYLUREA;

ACUTE CORONARY SYNDROME; AGED; ALBERTA; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FOLLOW-UP STUDIES; GLICLAZIDE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84890569821     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12173     Document Type: Article

References (48)

1. U. K. Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
2. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes II. Mortality results. Diabetes 1970; 19(Suppl): 789-830.
3. Pantalone KM, Kattan MW, Yu C et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab 2012; 14: 803-809.
4. Corrao G, Romio SA, Zambon A, Merlino L, Bosi E, Scavini M. Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy. Eur J Clin Pharmacol 2011; 67: 289-299.
5. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930-936.
6. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-2248.
7. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33: 119-124.
8. Danchin N, Charpentier G, Ledru F et al. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry. Diabetes Metab Res Rev 2005; 21: 143-149.
9. Juurlink DN, Gomes T, Shah BR, Mamdani MM. Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population. Diabet Med 2012; 29: 1524-1528.
10. Horsdal HT, Johnsen SP, Sondergaard F, Rungby J. Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study. Diabetologia 2008; 51: 567-574.
11. Halkin A, Roth A, Jonas M, Behar S. Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction. J Thromb Thrombolysis 2001; 12: 177-184.
12. Klamann A, Sarfert P, Launhardt V, Schulte G, Schmiegel WH, Nauck MA. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J 2000; 21: 220-229.
13. Jollis JG, Simpson RJ Jr, Cascio WE, Chowdhury MK, Crouse JR III, Smith SC Jr. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J 1999; 138(5 Pt 1): S376-380.
14. Abdelmoneim AS, Hasenbank SE, Seubert JM, Brocks DR, Light PE, Simpson SH. Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes Metab 2012; 14: 130-138.
15. Monami M, Balzi D, Lamanna C et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007; 23: 479-484.
16. Ashcroft FM, Rorsman P. Electrophysiology of the pancreatic beta-cell. Prog Biophys Mol Biol 1989; 54: 87-143.
17. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-1136.
18. Bolli R. Preconditioning: a paradigm shift in the biology of myocardial ischemia. Am J Physiol Heart Circ Physiol 2007; 292: H19-27.
19. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992; 70: 223-233.
20. Riveline JP, Danchin N, Ledru F, Varroud-Vial M, Charpentier G. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 2003; 29: 207-222.
21. Toombs CF, Moore TL, Shebuski RJ. Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardiovasc Res 1993; 27: 617-622.
22. Billman GE, Avendano CE, Halliwill JR, Burroughs JM. The effects of the ATP-dependent potassium channel antagonist, glyburide, on coronary blood flow and susceptibility to ventricular fibrillation in unanesthetized dogs. J Cardiovasc Pharmacol 1993; 21: 197-204.
23. Gamble JM, Eurich DT, Ezekowitz JA, Kaul P, Quan H, McAlister FA. Patterns of care and outcomes differ for urban versus rural patients with newly diagnosed heart failure, even in a universal healthcare system. Circ Heart Fail 2011; 4: 317-323.
24. Quan H, Sundararajan V, Halfon P et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-1139.
25. Lee DS, Stitt A, Wang X et al. Administrative hospitalization database validation of cardiac procedure codes. Med Care 2011.
26. Varas-Lorenzo C, Castellsague J, Stang MR, Tomas L, Aguado J, Perez-Gutthann S. Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database. Pharmacoepidemiol Drug Saf 2008; 17: 842-852.
27. O'Connor RE, Brady W, Brooks SC et al. Part 10: acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122(18 Suppl 3): S787-817.
28. McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 711-725.
29. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in case-control studies II. Types of controls. Am J Epidemiol 1992; 135: 1029-1041.
30. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics 1984; 40: 63-75.
31. Pantalone KM, Kattan MW, Yu C et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 2010; 33: 1224-1229.
32. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004; 27: 1218-1224.
33. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998; 36: 8-27.
34. Canadian Diabetes Association Clinical Practice Guidelines Expert C. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32(Suppl 1): S1-201.
35. Snee R. Validation of regression models: methods and examples. Technometrics 1977; 19: 415-428.
36. Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol 2008; 168: 329-335.
37. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.
38. Centre for Evidence Based Medicine - University of Oxford. Available from URL: http://www.cebm.net/index.aspx?o=1044. Accessed 3 March 2013.
39. Kristiansen SB, Lofgren B, Nielsen JM et al. Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes. Diabetologia 2011; 54: 451-458.
40. Muller DW, Topol EJ, Califf RM et al. Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J 1990; 119(2 Pt 1): 224-231.
41. Stricker BH, Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol 2010; 25: 245-251.
42. Konya H, Hasegawa Y, Hamaguchi T et al. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus. Metabolism 2010; 59: 1294-1299.
43. Englert HC, Heitsch H, Gerlach U, Knieps S. Blockers of the ATP-sensitive potassium channel SUR2A/Kir6.2: a new approach to prevent sudden cardiac death. Curr Med Chem Cardiovasc Hematol Agents 2003; 1: 253-271.
44. Sena CM, Louro T, Matafome P, Nunes E, Monteiro P, Seica R. Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet. Physiol Res 2009; 58: 203-209.
45. Davis TM, Parsons RW, Broadhurst RJ, Hobbs MS, Jamrozik K. Arrhythmias and mortality after myocardial infarction in diabetic patients Relationship to diabetes treatment. Diabetes Care 1998; 21: 637-640.
46. Evans JM, Ogston SA, Reimann F, Gribble FM, Morris AD, Pearson ER. No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis. Diabetes Obes Metab 2008; 10: 350-352.
47. Khalangot M, Tronko M, Kravchenko V, Kovtun V. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract 2009; 86: 247-253.
48. Horsdal HT, Johnsen SP, Sondergaard F et al. Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. Diabetes Metab Res Rev 2009; 25: 515-522.